A new systematic review looked at patient-reported outcomes associated with GLP-1 receptor agonists for managing type 2 diabetes.
In type 2 diabetes not on insulin, do incretin-based therapies compared to usual care improve patient satisfaction or quality of life?
The main outcome measures were the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and/or Impact of Weight on Quality Of Life-Lite (IWQOL-Lite).
The reviewers found eight clinical trials of the GLP-1 receptor agonists liraglutide, exenatide and long-acting exenatide which reported these outcome measures.
Treatment satisfaction (including perceptions of convenience and flexibility) was high, and generally higher with GLP-1 agonists in association with their greater glucose-lowering efficacy and tendency to facilitate weight loss.
Users of this research should consider:
- Whether the reviewers found all of the relevant publications.
- Did the reviewers produce a clear, prospective protocol for the review?
- Whether the inclusion criteria and quality assessment of individual studies was carried out by blind, independent reviewers.
- Whether it makes sense to combine the individual trials into an overall summary.
- What analytical approach was taken to identifying common themes between treatment modalities.
- Whether these benefits would be seen in clinical practice.
Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes. Diabetes Obes Metab. 2012 Mar 15.